AU2015214366B2 - 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof - Google Patents

6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof Download PDF

Info

Publication number
AU2015214366B2
AU2015214366B2 AU2015214366A AU2015214366A AU2015214366B2 AU 2015214366 B2 AU2015214366 B2 AU 2015214366B2 AU 2015214366 A AU2015214366 A AU 2015214366A AU 2015214366 A AU2015214366 A AU 2015214366A AU 2015214366 B2 AU2015214366 B2 AU 2015214366B2
Authority
AU
Australia
Prior art keywords
oxy
pyridin
trifluoromethyl
alkyl
quinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015214366A
Other languages
English (en)
Other versions
AU2015214366A1 (en
Inventor
Andrew Bogdan
Marlon D. Cowart
David A. Degoey
Tammie K. Jinkerson
John R. Koenig
Michael E. Kort
Bo Liu
Mark A. Matulenko
Derek W. Nelson
Meena V. Patel
Hillary Peltier
Marc J. Scanio
Brian D. Wakefield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of AU2015214366A1 publication Critical patent/AU2015214366A1/en
Application granted granted Critical
Publication of AU2015214366B2 publication Critical patent/AU2015214366B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU2015214366A 2014-02-06 2015-02-04 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof Ceased AU2015214366B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461936397P 2014-02-06 2014-02-06
US61/936,397 2014-02-06
PCT/US2015/014380 WO2015119998A1 (en) 2014-02-06 2015-02-04 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof

Publications (2)

Publication Number Publication Date
AU2015214366A1 AU2015214366A1 (en) 2016-08-18
AU2015214366B2 true AU2015214366B2 (en) 2019-04-18

Family

ID=52484589

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015214366A Ceased AU2015214366B2 (en) 2014-02-06 2015-02-04 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof

Country Status (14)

Country Link
US (3) US9452986B2 (enExample)
EP (1) EP3102569A1 (enExample)
JP (1) JP6532474B2 (enExample)
KR (1) KR20160118345A (enExample)
CN (1) CN106458985B (enExample)
AU (1) AU2015214366B2 (enExample)
BR (1) BR112016017996A2 (enExample)
CA (1) CA2938719A1 (enExample)
HK (1) HK1231471A1 (enExample)
IL (1) IL247014A0 (enExample)
MX (1) MX2016010056A (enExample)
RU (1) RU2016135637A (enExample)
SG (1) SG11201606367YA (enExample)
WO (1) WO2015119998A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
PT3805233T (pt) 2014-01-13 2024-04-15 Aurigene Oncology Ltd Enantiómeros (r) e (s) de n-(5-(3-hidroxipirrolidin-1-il)-2 morfolinooxazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)oxazole-carboxamida como inibidores de irak4 para o tratamento de cancro
KR20160118345A (ko) * 2014-02-06 2016-10-11 애브비 인코포레이티드 6-헤테로아릴옥시- 및 6-아릴옥시-퀴놀린-2-카복사미드 및 이의 용도
MX2016017147A (es) * 2014-06-20 2017-06-07 Aurigene Discovery Tech Ltd Compuestos de indazole substituidos como inhibidores de irak4.
MX2017003254A (es) * 2014-09-11 2017-10-12 Janssen Pharmaceutica Nv 2-azabiciclos sustituidos y su uso como moduladores de receptores de orexina.
EP3359151A4 (en) 2015-10-07 2019-08-14 Arizona Board of Regents on behalf of the University of Arizona CRMP2 SUMOYLATION INHIBITORS AND USES THEREOF
CN108513574B (zh) * 2015-10-09 2021-01-05 艾伯维公司 N-磺酰化吡唑并[3，4-b]吡啶-6-甲酰胺和使用方法
BR112019012822A2 (pt) 2016-12-22 2019-11-26 Bayer Ag 1,2,4-tiadiazolilpirrolonas e 1,2,4-tiadiazolil-hidantoínas e sais das mesmas e uso das mesmas como herbicidas
CA3056893A1 (en) 2017-03-31 2018-10-04 Aurigene Discovery Technologies Limited Compounds and compositions for treating hematological disorders
PL3615527T3 (pl) * 2017-06-30 2024-07-01 Elanco Animal Health Gmbh Nowe pochodne azachinoliny
RS65572B1 (sr) 2017-10-31 2024-06-28 Curis Inc Inhibitor irak4 u kombinaciji sa inhibitorom bcl-2 za upotrebu u lečenju kancera
US12234221B2 (en) 2018-07-09 2025-02-25 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting NAV1.8
CA3105748A1 (en) 2018-07-09 2020-01-16 Lieber Institute, Inc. Pyridazine compounds for inhibiting nav1.8
KR102812440B1 (ko) 2018-09-10 2025-05-26 가껭세이야꾸가부시기가이샤 신규한 헤테로방향족 아미드 유도체 및 이를 함유하는 약제
BR112021008741A2 (pt) 2018-11-09 2021-08-10 Vivace Therapeutics, Inc. compostos bicíclicos
US11976052B2 (en) * 2019-01-11 2024-05-07 Naegis Pharmaceuticals Inc. Leukotriene synthesis inhibitors
TWI849107B (zh) * 2019-04-16 2024-07-21 美商維瓦斯治療公司 雙環化合物
US12178821B2 (en) 2021-04-08 2024-12-31 Curis, Inc. Combination therapies for the treatment of cancer
KR20240134944A (ko) * 2022-01-18 2024-09-10 쳉두 캉홍 파마슈티칼 코., 엘티디. 방향족 융합 고리 nav1.8 억제제 및 이의 용도
TW202434557A (zh) 2022-11-09 2024-09-01 瑞士商先正達農作物保護股份公司 殺微生物之吡唑衍生物
WO2025078263A1 (en) 2023-10-11 2025-04-17 Syngenta Crop Protection Ag Microbiocidal pyridyl pyrazole derivatives
WO2025233384A1 (en) 2024-05-08 2025-11-13 Syngenta Crop Protection Ag Microbiocidal pyrazole compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007003419A1 (en) * 2005-07-04 2007-01-11 Karo Bio Ab Heterocyclic compounds as agonists for the thyroid receptor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1663994B1 (en) 2003-08-05 2012-03-07 Vertex Pharmaceuticals Incorporated Tetrahydroquinazoline compounds as inhibitors of voltage-gated ion channels
CN101044135B (zh) * 2004-10-19 2011-11-23 霍夫曼-拉罗奇有限公司 喹啉衍生物
RU2007146769A (ru) * 2005-05-16 2009-06-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Бициклические производные и их применение в качестве модуляторов ионых каналов
EP1924565B1 (en) * 2005-09-01 2016-09-14 F.Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p3x2/3 modulators
EP2046799B1 (en) 2006-04-26 2017-07-19 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
BRPI0719210A2 (pt) * 2006-10-12 2015-05-05 Xenon Pharmaceuticals Inc Uso de compostos espiro-oxindol como agentes terapêuticos
SA08290245B1 (ar) * 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
CN102448937A (zh) 2009-05-29 2012-05-09 拉夸里亚创药株式会社 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
WO2011058766A1 (en) * 2009-11-16 2011-05-19 Raqualia Pharma Inc. Aryl carboxamide derivatives as ttx-s blockers
EP2569285A1 (en) * 2010-05-10 2013-03-20 Gilead Sciences, Inc. Bifunctional quinoline derivatives
WO2012053186A1 (en) * 2010-10-18 2012-04-26 Raqualia Pharma Inc. Arylamide derivatives as ttx-s blockers
AU2014212426B8 (en) 2013-01-31 2018-05-10 Vertex Pharmaceuticals Incorporated Quinoline and Quinoxaline Amides as Modulators of Sodium Channels
KR20160118345A (ko) * 2014-02-06 2016-10-11 애브비 인코포레이티드 6-헤테로아릴옥시- 및 6-아릴옥시-퀴놀린-2-카복사미드 및 이의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007003419A1 (en) * 2005-07-04 2007-01-11 Karo Bio Ab Heterocyclic compounds as agonists for the thyroid receptor

Also Published As

Publication number Publication date
IL247014A0 (en) 2016-09-29
RU2016135637A (ru) 2018-03-12
HK1231471A1 (zh) 2017-12-22
US20160355482A1 (en) 2016-12-08
KR20160118345A (ko) 2016-10-11
JP6532474B2 (ja) 2019-06-19
US20170226062A9 (en) 2017-08-10
RU2016135637A3 (enExample) 2018-08-27
AU2015214366A1 (en) 2016-08-18
CA2938719A1 (en) 2015-08-13
US20150218102A1 (en) 2015-08-06
US20180334435A1 (en) 2018-11-22
EP3102569A1 (en) 2016-12-14
US9452986B2 (en) 2016-09-27
WO2015119998A1 (en) 2015-08-13
CN106458985B (zh) 2019-05-03
CN106458985A (zh) 2017-02-22
SG11201606367YA (en) 2016-09-29
US9969693B2 (en) 2018-05-15
MX2016010056A (es) 2016-11-15
JP2017505327A (ja) 2017-02-16
BR112016017996A2 (pt) 2017-08-08

Similar Documents

Publication Publication Date Title
AU2015214366B2 (en) 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof
JP7688210B2 (ja) Ｂｃｌ－２阻害剤
AU2024200566A1 (en) Pyridazinones as PARP7 inhibitors
EP2534151B1 (en) 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds
AU2016341520A1 (en) Benzolactam compounds as protein kinase inhibitors
KR102794907B1 (ko) Pde1 억제제로서의 치환된 푸라노피리미딘 화합물
US9777020B2 (en) Furo-3-carboxamide derivatives and methods of use
US9783527B2 (en) Indazole ureas and method of use
AU2011212453B2 (en) 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds
DK2534151T3 (en) 8-methyl-1-phenyl-imidazo [1,5-a] pyrazin-COMPOUNDS
EA043978B1 (ru) ИНГИБИТОРЫ Bcl-2

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired